Optimisation of glaucoma therapy through management of ocular surface diseases

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00035847

Enrollment

Registered

2025-01-09

Start date

2025-01-06

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H40.1

Interventions

Group 1: Antiglaucomatous combination preparations are separated into individual preparations Group 2: Anti-inflammatory eye drops for one week, eyelid margin hygiene twice daily, change of antiglauco

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Women and men of all ages with primary open-angle glaucoma and ocular surface disease through localised glaucoma therapy

Exclusion criteria

Exclusion criteria: Acute tensiodecompensation with IOP values from 30mmHg Non-consenting persons

Design outcomes

Primary

Measure	Time frame
Reduction of the applanatory intraocular pressure measured in mmHg. Measurements are taken during the baseline examination, as well as at 1 and 3 months follow-up.	—

Secondary

Measure	Time frame
OCT, visual field measurement, Schirmer test, clinical dry eye score	—

Countries

Germany

Contacts

Public ContactMaximilian Binter

Universitätsklinik für Augenheilkunde der Medizinischen Hochschule Hannover

binter.maximilian@mh-hannover.de0511 532-3061

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026